Combination therapy with olmesartan and temocapril ameliorates renal damage and upregulates the klotho gene in 5/6 nephrectomized spontaneously hypertensive rats

Yonago Acta Medica

Volumn 52, Issue 1, 2009, Pages 27-35

  Maeta, Satoko ^a   Munemura, Chishio ^a   Fukui, Takeaki ^a   Ishida, Chihiro ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme; Cardiovascular disease; Chronic kidney disease; Inhibitor; Klotho gene

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CREATININE; MESSENGER RNA; OLMESARTAN; TEMOCAPRIL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DOWN REGULATION; DRUG MEGADOSE; GENE; GENE EXPRESSION; GLOMERULOSCLEROSIS; KIDNEY INJURY; KLOTHO GENE; LOW DRUG DOSE; MALE; NEPHRECTOMY; NONHUMAN; RAT; RENAL PROTECTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

EID: 66749130230     PISSN: 05135710     EISSN: 13468049     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Aizawa H, Saito Y, Nakamura T, Inoue M, Imanari T, Ohyama Y, et al. Downregulation of the Klotho gene in the kidney under sustained circulatory stress in rats. Biochem Biophys Res Commun 1998;249:865-871. (Pubitemid 28441930)
2. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263-272. (Pubitemid 38224234)
3. Dabek J, Kulach A, Monastyrska-Cup B, Gasior Z. Transforming growth factor beta and cardiovascular diseases: the other facet of the 'protective cytokine'.Pharmacol Rep 2006;58:799-805.
4. de Cavanagh EM, Inserra F, Ferder L, Fraga CG. Enalapril and captopril enhance glutathione-depen-dent antioxidant defenses in mouse tissues. Am J Physiol Regul Integr Comp Physiol 2000;278:R572-R577. (Pubitemid 30158114)
5. de Cavanagh EM, Inserra F, Toblli J, Stella I, Fraga CG, Ferder L. Enalapril attenuates oxidative stress in diabetic rats. Hypertension 2001;38:1130-1136. (Pubitemid 34252818)
6. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005;45:39-47. (Pubitemid 40038043)
7. de Zeeuw D, Remuzzi G, Parving, HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921-927.
8. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K,Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 2003;26:691-697. (Pubitemid 37258655)
9. Fan YY, Baba R, Nagai Y, Miyatake A, Hosomi N, Kimura S, et al. Augmentation of intrarenal angio-tensin II levels in uninephrectomized aldosterone/ salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. Hypertens Res 2006;29:169-178.
10. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005;16:1135-1140 (Pubitemid 41710325)
11. Fujimoto S, Satoh M, Horike H, Hatta H, Haruna Y, Kobayashi S, et al. Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens Res 2008;31:305-313.
12. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int 1992;42:1020-1029.
13. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004;66:1-9. (Pubitemid 38870076)
14. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003;14:992-999. (Pubitemid 36359280)
15. Kanazawa M, Kohzuki M, Yoshida K, Kurosawa H, Minami N, Saito T, et al. Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effect of ACE inhibitor monotherapy in a spontaneÂous hypertensive rat with renal ablation. Hypertens Res 2002;25:447-453.
16. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, et al. Severely reduced production of klotho in human chronic renal failure kidney. Bio-chem Biophys Res Commun 2001;280:1015-1020.
17. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51. (Pubitemid 27494749)
18. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, et al. Suppression of aging in mice by the hormone Klotho. Science 2005;309:1829-1833. (Pubitemid 41325087)
19. Long DA, Price KL, Herrera-Acosta J, Johnson RJ. How does angiotensin II cause renal injury? Hypertension 2004;43:722-723. (Pubitemid 38405576)
20. Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T, et al. In vivo klotho gene transfer amelio-rates angiotensin II-induced renal damage. Hypertension 2002; 39:838-843.
21. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (CO-OPERATE): a randomised controlled trial. Lancet 2003;361:117-124. (Pubitemid 36092015)
22. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropa-thy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
23. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 2008;19:1459-1462.
24. Saito K, Ishizaka N, Aizawa T, Sata M, Iso-O N,Noiri E, et al. Role of aberrant iron homeostasis in the upregulation of transforming growth factor-beta1 in the kidney of angiotensin II-induced hypertensive rats. Hypertens Res 2004;27:599-607. (Pubitemid 39335077)
25. Saito T, Sumithran E, Glasgow EF, Atkins RC. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 1987;32:691-699. (Pubitemid 17152399)
26. Saito Y, Nakamura T, Ohyama Y, Suzuki T, Iida A, Shiraki-Iida T, et al. In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Com-mun 2000;276:767-772.
27. Saito Y, Yamagishi T, Nakamura T, Ohyama Y, Aizawa H, Suga T, et al. Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 1998;248:324-329.
28. Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007;30:1351-1356. (Pubitemid 46871137)
29. Shigenaga MK, Gimeno CJ, Ames BN. Urinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc Natl Acad Sci U S A 1989;86:9697-9701. (Pubitemid 20030700)
30. Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T. Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure.Hypertension 2002;40:834-839. (Pubitemid 35434903)
31. Wolf G. Angiotensin II as a mediator of tubuloint-erstitial injury. Nephrol Dial Transplant 2000;15 Suppl 6:61-63.
32. Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 2005;280:38029-38034. (Pubitemid 41642417)
33. Yao L, Kobori H, Rahman M, Seth DM, Shokoji T, Fan Y, et al. Olmesartan improves endothelin-induced hypertension and oxidative stress in rats.Hypertens Res 2004;27:493-500.
34. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of angiotensin-converting-en-zyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153. (Pubitemid 30051645)